Effect of chromium on diabetes mellitus type2 treatment

Effect of chromium on the metabolic index in patients with diabetes mellitus type2

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013012812311N1

Enrollment

Registered

2013-03-07

Start date

2012-05-14

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Diabetes mellitus

Interventions

Intervention 1: Intervention group: chromium picolinat 200 microgram tablet, once daily during 3 mounth. Intervention 2: control group: placebo, once daily during 3 mounth.

Treatment - Drugs

Placebo

Intervention group: chromium picolinat 200 microgram tablet, once daily during 3 mounth.

control group: placebo, once daily during 3 mounth.

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. HbA1c=10%, HbA1c=7%; 2. DM2; 3. BMI=35, BMI=25; 4. Stability of antidiabetic treatment during recent 3 mounths; 5. Age 30-65 years. Exclusion criteria: 1. Cr?1.5 (men), Cr>1.4 (female); 2. Liver function test (ALT, AST) >2 fold of upper limit normal; 3. Pregnancy; 4. Heart Failure; 5. Chronic Liver disease; 6. Uncontrolled hypertension; 7. Immunosupression disease and immunosupresive therapy; 8. Alcohol use and other drug abuse; 9. Psychological unhealthy; 10. Confined to bed during recent 1 years.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Uric acid. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;HbA1c. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;HDL- C. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;LDL- C. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;TG. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;FPG. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;BS 2hpp. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;BMI. Timepoint: Before intervension & 3 months later. Method of measurement: kg/m2.;Creatinine. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.	—

Measure

Time frame

Uric acid. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;HbA1c. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;HDL- C. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;LDL- C. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;TG. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;FPG. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;BS 2hpp. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.;BMI. Timepoint: Before intervension & 3 months later. Method of measurement: kg/m2.;Creatinine. Timepoint: Before intervension & 3 months later. Method of measurement: mg/dl- labratory kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDoctor Azam Arfanifar

Shahid Beheshti University of Medical Sciences

erfanifarazam@yahoo.com+98 21 5541 9005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026